ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection
Compensated Cirrhosis

Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir
Drug: Dasabuvir

First Posted Date: 2014-08-19

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT02219503

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Phase 3

Completed

Conditions: Chronic Hepatitis C
Decompensated Cirrhosis
Hepatitis C Virus

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir
Drug: ribavirin

First Posted Date: 2014-08-19

Last Posted Date: 2017-07-11

Lead Sponsor: AbbVie

Target Recruit Count: 36

Registration Number: NCT02219477

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2014-08-19

Last Posted Date: 2023-04-07

Lead Sponsor: AbbVie

Target Recruit Count: 1596

Registration Number: NCT02219490

Locations: 🇳🇴
Akershus Universitetssykehus_MAIN /ID# 132212, Lorenskog, Akershus, Norway
🇩🇰
Odense University Hospital /ID# 131029, Odense C, Syddanmark, Denmark
🇩🇰
Aarhus Univ Hospital, Skejby /ID# 131030, Aarhus, Denmark

and more 184 locations

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV) Infection

Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir
Drug: Dasabuvir
Drug: Ribavirin (RBV)

First Posted Date: 2014-08-15

Last Posted Date: 2016-06-29

Lead Sponsor: AbbVie

Target Recruit Count: 36

Registration Number: NCT02216422

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: veliparib (ABT-888)

First Posted Date: 2014-08-07

Last Posted Date: 2018-05-07

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT02210663

Locations: 🇯🇵
Site Reference ID/Investigator# 128056, Hidaka-shi, Japan
🇯🇵
Site Reference ID/Investigator# 128057, Tokyo, Japan
🇯🇵
Site Reference ID/Investigator# 129976, Hyogo, Japan

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Phase 3

Completed

Conditions: Hepatitis C Virus
Compensated Cirrhosis
End-stage Renal Disease
Chronic Hepatitis C
Severe Renal Impairment

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir
Drug: Ribavirin

First Posted Date: 2014-08-01

Last Posted Date: 2017-11-09

Lead Sponsor: AbbVie

Target Recruit Count: 68

Registration Number: NCT02207088

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab

First Posted Date: 2014-07-30

Last Posted Date: 2019-11-08

Lead Sponsor: AbbVie

Target Recruit Count: 110

Registration Number: NCT02203851

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Myelogenous Leukemia
Treatment Naive AML

Interventions: Drug: ABT-199
Drug: Posaconazole
Drug: Azacitidine
Drug: Decitabine

First Posted Date: 2014-07-30

Last Posted Date: 2023-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 212

Registration Number: NCT02203773

Locations: 🇺🇸
Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States

and more 20 locations

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

Phase 4

Completed

Conditions: Rheumatoid Arthritis
Musculoskeletal and Connective Tissue Diseases

Interventions: Other: Placebo
Biological: Adalimumab

First Posted Date: 2014-07-24

Last Posted Date: 2019-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 149

Registration Number: NCT02198651

Locations: 🇨🇦
St. Joseph's Healthcare /ID# 149233, Hamilton, Ontario, Canada
🇺🇸
Westlake Medical Research (WMR) Clinical Trials /ID# 155386, Thousand Oaks, California, United States
🇩🇪
Asklepios Klinik /ID# 129146, Bad Abbach, Germany

and more 67 locations

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Adalimumab
Drug: Methotrexate

First Posted Date: 2014-07-22

Last Posted Date: 2018-03-19

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02196701

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy